|View printer-friendly version|
Showcasing Scientific Excellence
Throughout the meeting, Charles River’s experts will present the Company’s industry-leading oncology capabilities and highlight the latest advancements by presenting innovative applications for CRISPR/Cas9, immuno-oncology, in vitro assays, and more.
Noteworthy posters include:
Determination of signal transduction pathway activity in
patient-derived xenograft models in comparison with clinical patient
tumor samples for a variety of human cancer types (Presented:
Monday, April 16, 8:00 a.m.-12:00 p.m.) This project, completed with Philips Molecular Pathway Diagnostics, describes an analysis method which identifies and quantifies activity in the cell signaling pathways of Charles River’s patient-derived xenograft (PDX) tumor models.
A translational platform using primary human immune cells in
vitro, syngeneic and humanized models in vivo to support
and advance immuno-oncology drug discovery (Presented:
Monday, April 16, 8:00 a.m.-12:00 p.m.) Researchers established a translational immuno-oncology platform with the capability of progressing biologics or small-molecule modulators of immune response from in vitro and ex vivo through in vivo assays, including humanized models.
Quantitative measurement of immune-modulatory mediators within
tumors of freely moving mice utilizing in vivo microdialysis
Tuesday, April 17, 8:00 a.m.-12:00 p.m.) Leveraging microdialysis in tumors, researchers monitored changes in biochemical elements within tumors to better understand cancer biology in the development of novel therapies.
A full schedule of Charles River’s activities during AACR 2018 is available online. Reprints of each poster will be available in Booth #1615 during the conference and Charles River experts will be available for meetings to discuss how an integrated approach can support drug discovery and development programs from hit ID to IND. Throughout the conference, Charles River will be providing live updates on the Eureka Blog, including reviews of scientific sessions and input on the research being presented.
Bioinformatic Additions to Compendium
Select Humanization Kit
Recently, Charles River and HemaCare Corporation (OTCBB: HEMA) formed a strategic partnership to advance human immune system research by developing a more efficient and reliable method of working with humanized mice. Through the partnership, HemaCare’s peripheral blood mononuclear cells (PBMCs) are paired with Charles River’s NCG triple immunodeficient mouse. This NCG/PBMC Select Humanization Kit is the first of its kind in the industry and provides both the NCG mouse and vials of prescreened human PBMCs, allowing researchers to efficiently develop humanized mouse models on their own timeline.
- “Our scientists are exploring groundbreaking applications of innovative tools and technologies across oncology research. From CRISPR to in vitro immuno-oncology to microdialysis, our deep scientific bench affords us a unique opportunity to leverage learnings from different therapeutic areas and apply them to oncology. We’re proud to showcase our body of work at AACR this year.” –Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Charles River
- “The continued expansion of our Tumor Model Compendium highlights the significant role bioinformatics plays in oncology research. Scientists require data to conduct their research efficiently and effectively. Our Compendium puts the power of our data in their hands—eliminating steps and driving the development process forward.” –Aidan Synnott, Executive Director, Discovery Oncology, Charles River
The mission of the
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Charles River Laboratories International, Inc.
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations